Preventative health startups draw record €822m in European funding
A 162% surge in early-stage funding for preventative digital health companies signals a market shift toward technologies designed to reduce Europe's looming $8tn healthcare burden.
European preventative health startups raised €822.2m in the first half of 2024, a 162% increase from €116.5m in the same period last year. Total deal volume jumped 106% to €383.0m, with early-stage investments accounting for 30.7% of the activity. The capital influx marks a decisive pivot away from the telemedicine and digital pharmacy models that dominated the first wave of the pandemic.
A demographic imperative
The shift in venture capital mirrors a looming demographic crisis. By 2050, one in four Europeans will be over 65. The World Health Organization estimates the continent faces an $8tn gap in its $14tn healthcare systems, which currently represent 9% of GDP. In the EU, healthcare spending grew to an average of 8.8% of GDP, an 884% increase that saw costs swell from $1.7tn to $2.5tn by 2022. Investors are now betting that preventative care targeting conditions like diabetes, cardiovascular disease and oncology before they become chronic is the only viable path to sustainable public finances.
Early-stage deal flow accelerates
The funding is broadly distributed across wearable diagnostics and AI-driven platforms. A Berlin-based pre-seed startup raised €4m in September 2024 backed by Novo/Nordisk Seed and Y Combinator. In London, IME(UK) secured $4.7m in October 2024 in a round led by Founders Fund, with participation from Sequoia Capital and LocalGlobe. The company is developing a non-invasive wearable glucose monitor that predicts spikes 20 minutes in advance.
Munich-based Resilience, which combines AI diagnostics with clinical research to accelerate drug discovery, closed a £3m round from the European Innovation Council in 2024. Barcelona's Wako, a maker of continuous monitoring wearable ECGs, raised a €3.5m seed round in June 2024 led by Seaya Ventures before signing a partnership with Roche in September 2024.
Vienna Bio secured $9m in November 2024 from AXA Venture to advance its early cancer detection platform, while Milan's Hippocratic announced $15m from the European Innovation Fund in October 2024 for its oncology-focused AI models. On the consumer side, Finnish smart ring maker Oura closed a $200m Series D in December 2024 led by F-Prime Capital and EGL Ventures.
